Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00780104 · ClinicalTrials.gov registry record · Phase 1
Sirolimus in Combination With MEC in High Risk Myeloid Leukemias
A Phase 1 study of Leukemia and AML, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00780104 is a Phase 1 study of Leukemia and AML that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 16 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00780104, a Phase 1 study of Leukemia and AML, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the side effects of sirolimus (rapamycin) given in combination with chemotherapy (Mitoxantrone + Etoposide + Cytarabine (MEC)) on high risk myeloid leukemias.
Conditions Studied
Interventions
- DRUG Rapamycin, Mitoxantrone, Etoposide, Cytarabine
- DRUG Rapamycin + MEC
Study Locations (1)
Pennsylvania
- University of Pennsylvania Abramson Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-07 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00780104
The ClinicalTrials.gov registry entry for NCT00780104 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (97% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Rapamycin, Mitoxantrone, Etoposide, Cytarabine is the first listed.
NCT00780104 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00780104 about?
NCT00780104 is a clinical study titled "Sirolimus in Combination With MEC in High Risk Myeloid Leukemias". The purpose of this study is to evaluate the side effects of sirolimus (rapamycin) given in combination with chemotherapy (Mitoxantrone + Etoposide + Cytarabine (MEC)) on high risk myeloid leukemias.
What is the current status of trial NCT00780104?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2007-07. Estimated completion is 2010-06.
What conditions does trial NCT00780104 study?
This clinical trial studies the following conditions: Leukemia, AML, CML, Myeloid Leukemias.
What interventions are being tested in trial NCT00780104?
The interventions under investigation include: Rapamycin, Mitoxantrone, Etoposide, Cytarabine (DRUG), Rapamycin + MEC (DRUG).
Who is sponsoring clinical trial NCT00780104?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00780104 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.